2022
Gene Sequencing Identifies Perturbation in Nitric Oxide Signaling as a Nonlipid Molecular Subtype of Coronary Artery Disease
Khera AV, Wang M, Chaffin M, Emdin CA, Samani NJ, Schunkert H, Watkins H, McPherson R, Erdmann J, Elosua R, Boerwinkle E, Ardissino D, Butterworth A, Di Angelantonio E, Naheed A, Danesh J, Chowdhury R, Krumholz H, Sheu W, Rich S, Rotter J, Chen Y, Gabriel S, Lander E, Saleheen D, Kathiresan S. Gene Sequencing Identifies Perturbation in Nitric Oxide Signaling as a Nonlipid Molecular Subtype of Coronary Artery Disease. Circulation Genomic And Precision Medicine 2022, 15: e003598. PMID: 36215124, PMCID: PMC9771961, DOI: 10.1161/circgen.121.003598.Peer-Reviewed Original ResearchMeSH KeywordsCholesterolCoronary Artery DiseaseHumansHypercholesterolemiaNitric OxidePolymorphism, GeneticConceptsMolecular subtypesCAD riskHigher systolic blood pressureCoronary artery disease patientsEndothelial nitric oxide synthase geneDamaging missense variantsRisk of CADSystolic blood pressureCoronary artery diseaseRisk of hypertensionNitric oxide synthase geneMissense variantsNitric oxide synthesisRare variantsOxide synthase geneDiscrete molecular subtypesNitric Oxide SignalingLow density lipoprotein receptor geneArtery diseaseBlood pressureEndothelial functionVascular toneDisease patientsCAD casesCholesterol concentrationsSex-Specific Risk Factors Associated With First Acute Myocardial Infarction in Young Adults
Lu Y, Li SX, Liu Y, Rodriguez F, Watson KE, Dreyer RP, Khera R, Murugiah K, D’Onofrio G, Spatz ES, Nasir K, Masoudi FA, Krumholz HM. Sex-Specific Risk Factors Associated With First Acute Myocardial Infarction in Young Adults. JAMA Network Open 2022, 5: e229953. PMID: 35503221, PMCID: PMC9066284, DOI: 10.1001/jamanetworkopen.2022.9953.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesDiabetes MellitusFemaleHumansHypercholesterolemiaHypertensionMaleMyocardial InfarctionNutrition SurveysRisk FactorsYoung AdultConceptsFirst acute myocardial infarctionAcute myocardial infarctionPsychosocial risk factorsRisk factor profilePopulation attributable fractionRisk factor associationsRisk factorsOdds ratioYoung womenAMI subtypesMyocardial infarctionPrevention of AMIType 1 acute myocardial infarctionFactor profileRisk of AMITraditional cardiovascular risk factorsSex-specific risk factorsFactor associationsYoung adultsRisk factor modificationCardiovascular risk factorsStrong associationNutrition Examination SurveyCase-control studyPopulation-based controls
2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitorsTreatment of Cholesterol in 2017
Krumholz HM. Treatment of Cholesterol in 2017. JAMA 2017, 318: 417-418. PMID: 28738130, DOI: 10.1001/jama.2017.6753.Peer-Reviewed Original Research
2014
Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010
Ross JS, Frazee SG, Garavaglia SB, Levin R, Novshadian H, Jackevicius CA, Stettin G, Krumholz HM. Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010. JAMA Internal Medicine 2014, 174: 1486-1493. PMID: 25070672, PMCID: PMC4208827, DOI: 10.1001/jamainternmed.2014.3404.Peer-Reviewed Original ResearchConceptsLipid-lowering agentsENHANCE trialEzetimibe useEzetimibe initiationPharmacy benefit managersUse of ezetimibeProgression of atherosclerosisAdults 18 yearsHalf of adultsAtherosclerosis regression trialsPredictors of useBenefit managersEzetimibe monotherapyMonotherapy usersMedication initiationEligible adultsPrescription claimsCholesterol levelsRetrospective analysisMAIN OUTCOMEAdult beneficiariesUS census divisionsDiscontinuationRegression trialsEzetimibeThe Guidelines Battle on Starting Statins
D'Agostino RB, Ansell BJ, Mora S, Krumholz HM. The Guidelines Battle on Starting Statins. New England Journal Of Medicine 2014, 370: 1652-1658. PMID: 24758622, DOI: 10.1056/nejmclde1314766.Peer-Reviewed Original ResearchImpact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada
Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada. American Heart Journal 2014, 167: 683-689. PMID: 24766978, PMCID: PMC4215424, DOI: 10.1016/j.ahj.2014.01.014.Peer-Reviewed Original ResearchConceptsUse of ezetimibeENHANCE trialEzetimibe useProgression of atherosclerosisMain outcome measuresAtherosclerosis regression trialsMonthly numberOutcome measuresRegression trialsEzetimibeIMS HealthCommon evidence baseEvidence baseTrialsUnited StatesUtilization patternsFurther investigationDifferent utilization patternsPopulationDifferent patternsUse trendsAtherosclerosisSimvastatinProgression
2013
Prevalence of Traditional Cardiac Risk Factors and Secondary Prevention Among Patients Hospitalized for Acute Myocardial Infarction (AMI): Variation by Age, Sex, and Race
Leifheit-Limson EC, Spertus JA, Reid KJ, Jones SB, Vaccarino V, Krumholz HM, Lichtman JH. Prevalence of Traditional Cardiac Risk Factors and Secondary Prevention Among Patients Hospitalized for Acute Myocardial Infarction (AMI): Variation by Age, Sex, and Race. Journal Of Women's Health 2013, 22: 659-666. PMID: 23841468, DOI: 10.1089/jwh.2012.3962.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overBlack or African AmericanBody Mass IndexCounselingDiabetes Mellitus, Type 2FemaleHospitalizationHumansHypercholesterolemiaHypertensionLife StyleMaleMiddle AgedMyocardial InfarctionObesityPrevalenceProspective StudiesRisk FactorsSecondary PreventionSex FactorsSmokingSmoking CessationSocioeconomic FactorsWhite PeopleConceptsCardiac risk factorsAcute myocardial infarctionSecondary prevention effortsTraditional cardiac risk factorsLipid-lowering medicationsRisk factorsWhite patientsAMI patientsMyocardial infarctionPrevention effortsGreater risk factor burdenMultiple cardiac risk factorsRisk factor burdenYoung black patientsYoung white patientsSecondary prevention strategiesRisk factor prevalenceHigh-risk subgroupsMultiple risk factorsBlack womenAge-sex groupsOlder patientsSecondary preventionYounger patientsFactor prevalence
2010
Emphasizing the Burden of Proof
Krumholz HM. Emphasizing the Burden of Proof. Circulation Cardiovascular Quality And Outcomes 2010, 3: 565-567. PMID: 21081745, DOI: 10.1161/circoutcomes.110.959577.Peer-Reviewed Original ResearchShifting views on lipid lowering therapy
Krumholz HM, Hayward RA. Shifting views on lipid lowering therapy. The BMJ 2010, 341: c3531. PMID: 20667950, DOI: 10.1136/bmj.c3531.Peer-Reviewed Original ResearchBeyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey
Spatz ES, Ross JS, Desai MM, Canavan ME, Krumholz HM. Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. American Heart Journal 2010, 160: 115-121. PMID: 20598981, PMCID: PMC3025407, DOI: 10.1016/j.ahj.2010.04.013.Peer-Reviewed Original ResearchConceptsTreatment of hypertensionNutrition Examination SurveyInsurance statusMedication treatmentExamination SurveyNational HealthUsual sourceAdult Treatment Panel III recommendationsJoint National Committee 7Multivariable logistic regression modelingInsurance coverageSeparate multivariable modelsChronic disease managementLogistic regression modelingHigh-quality careRace/ethnicityCardiovascular diseaseMultivariable modelStratified analysisHypertensionHypercholesterolemiaRegular sourceCareDisease managementIndependent effects
2008
Use of Ezetimibe in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of Ezetimibe in the United States and Canada. New England Journal Of Medicine 2008, 358: 1819-1828. PMID: 18375999, DOI: 10.1056/nejmsa0801461.Peer-Reviewed Original ResearchConceptsLipid-lowering agentsLow-density lipoprotein cholesterolLipid-lowering guidelinesRatio of prescriptionsUse of ezetimibeTreatment of hyperlipidemiaStatin useCohort studyLipoprotein cholesterolSecondary preventionStatin prescriptionClinical outcomesPrescribing practicesEzetimibeIMS HealthUnited StatesPrescriptionMonthly numberFirst optionDistinct patterns
2005
Knowledge of Cholesterol Levels and Targets in Patients With Coronary Artery Disease
Cheng S, Lichtman JH, Amatruda JM, Smith GL, Mattera JA, Roumanis SA, Krumholz HM. Knowledge of Cholesterol Levels and Targets in Patients With Coronary Artery Disease. Preventive Cardiology 2005, 8: 11-17. PMID: 15722689, DOI: 10.1111/j.1520-037x.2005.3939.x.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseHigh-density lipoproteinLow-density lipoproteinCholesterol targetsArtery diseaseCholesterol levelsMultiple cardiac risk factorsCardiac risk factorsTotal cholesterol levelsTotal cholesterol valuesRisk factorsCardiovascular diseaseCholesterol valuesPrevious historyPatientsLipoproteinDiseaseCollege educationWomenNonwhitesEducation effortsNational targetsTargetCholesterol
1999
Editorial
Chen YT, Krumholz HM. Editorial. Nutrition 1999, 15: 242-244. PMID: 10198923, DOI: 10.1016/s0899-9007(98)00187-7.Peer-Reviewed Original Research